Severe Asthma Management
Recommendations for the management of severe asthma from the Global Initiative for Asthma (GINA).
Asthma
Asthma Prevalence May Be Higher in Elderly With Behavioral Health Issues
Because of the prevalence of behavioral health issues in elderly patients with asthma, appropriate behavioral health treatment may improve patient outcomes.
Pulse Oximetry, Vital Signs May Predict Hospital LOS in Pediatric Asthma Exacerbations
Heart rate, respiratory rate, and oxygen saturation (SpO2) levels with percentile-based cutoffs can predict the risk of prolonged hospitalization in pediatric asthma exacerbations.
Adding Umeclidinium to ICS/LABA Improves Lung Function, Exacerbation Rate in Asthma
Patients with asthma that is poorly controlled by ICS/LABA therapy may experience improvement in lung function with the addition of umeclidinium and/or doubling of the corticosteroid fluticasone furoate.
Adding Reslizumab May Benefit Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
Adding reslizumab to mometasone furoate enhanced clinical benefits of the intranasal corticosteroid alone in patients with uncontrolled chronic rhinosinusitis with nasal polyps and peripheral eosinophilia.
Dupilumab Demonstrates Long-Term Efficacy, Safety for Improving Asthma Control
Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks
Dupilumab Reduces Severe Asthma Exacerbations, With/Without Reduction in FeNO
Dupilumab significantly reduced severe asthma exacerbations and improved prebronchodilator FEV1 in patients with baseline FeNO greater than or equal to 25 ppb with/without substantial FeNO reduction.
Benralizumab Achieves Clinically Meaningful Improvements in Asthma, Nasal Polyposis
The majority of patients with asthma and nasal polyposis who were treated with benralizumab were considered “comprehensive responders.”
Tezepelumab Cuts Exacerbations in Severe Asthma Trial
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Benralizumab Reduces OCS Use in Severe Asthma Trial
Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…
